Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study

20260 citationsJournal Articlegold Open Access

Authors

Erik Sörstedt · Sahlgrenska University Hospital

George M. Nduva · GlaxoSmithKline (Sweden)

Fredrik Månsson · Malmö University

Åsa Mellgren · Sahlgrenska University Hospital

Johanna Repits · GlaxoSmithKline (Sweden)

E. Fernvik · ViiV Healthcare (United Kingdom)

Adam Stubbs ·

Abstract

In this long-term, real-world, national cohort, switching to DTG+3TC was associated with low rates of VF and antiretroviral therapy resistance, indicating that eligible individuals can be switched to DTG+3TC without increased risk of VF.

Topics & Keywords

HIV/AIDS drug development and treatment HIV-related health complications and treatments HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the International AIDS Society

Volume 29, Issue 3, pp. e70054-e70054

DOI: 10.1002/jia2.70054

Field-Weighted Citation Impact: 0.00